


To achieve capital growth.
| Name | % Net Assets |
|---|---|
| Sanofi-Aventis | 4.5% |
| Credit Suisse | 3.8% |
| Novartis | 3.5% |
| Total | 3.5% |
| Roche | 3.3% |
| Unilever | 3.3% |
| Siemens | 3.2% |
| Banco Santander | 3.2% |
| Anheuser-Busch | 2.9% |
| Zurich Financial Services | 2.8% |
| Key | % Net Assets |
|---|---|
| 4.5% | |
| 3.8% | |
| 3.5% | |
| 3.5% | |
| 84.7% |
| Date | 19-Aug-2025 |
|---|---|
| NAV | 1,097.05p |
| Currency | GBP |
| Change | 8.69p |
| % | 0.80% |
| YTD change | 125.65p |
| YTD % | 12.94% |
| Fund Inception | 27/08/1986 |
|---|---|
| Fund Manager | Aaron Barnfather / Mark Little and team |
| TER | 1.57 (31-Mar-2014) |
| Minimum Investment | |
|---|---|
| Initial | £2000 |
| Additional | £500 |
| Savings | £75 |
| Charges | |
|---|---|
| Initial | 3.75% |
| Annual Mang't | 1.50% |
| Exit | n/a |
| Name | % |
|---|---|
| Standard deviation | 0.02 |
| Sharpe ratio | 0.06 |
You are here: research